I. Introduction

Oncologic emergencies are acute, life-threatening conditions that arise from the structural or metabolic effects of a malignancy or its treatment. These events frequently necessitate ICU-level interventions. Critical care pharmacists play an indispensable role in optimizing patient outcomes by recognizing early warning signs, understanding the underlying mechanistic pathways, and guiding targeted pharmacotherapy.

• The rising number of ICU admissions for patients with cancer reflects both the success of advanced therapies extending life and an aging population with more comorbidities.
• Common emergencies span multiple domains, including metabolic disturbances (tumor lysis syndrome, hypercalcemia), infectious complications (neutropenic fever), vascular obstruction (SVC syndrome), and neurologic compromise (spinal cord compression).
• Early and effective interdisciplinary collaboration among oncology, critical care, and pharmacy teams is crucial for streamlining diagnosis, implementing appropriate monitoring, and ensuring timely therapeutic adjustments.

II. Epidemiologic Trends

The incidence, requirement for ICU transfer, and associated mortality of oncologic emergencies vary significantly by the type of emergency and the underlying malignancy. Patients with cancer now comprise up to 20% of all ICU admissions. While febrile neutropenia is the most frequent reason for ICU transfer, metabolic emergencies like tumor lysis syndrome (TLS) and hypercalcemia of malignancy also contribute significantly. Mechanical emergencies such as spinal cord compression and SVC syndrome are less common but carry high morbidity.

Hematologic malignancies like leukemia and lymphoma are primary drivers of high rates of TLS, whereas solid tumors (e.g., lung, breast, prostate) are more often responsible for mechanical and structural emergencies.

III. Pathophysiology of ICU-Relevant Emergencies

Each oncologic emergency follows a distinct cellular or structural pathway that, if unchecked, precipitates rapid clinical decline. Understanding these mechanisms is key to both prevention and treatment.

3.1 Superior Vena Cava (SVC) Syndrome

SVC syndrome results from the obstruction of venous return from the head, neck, and upper extremities to the right atrium, leading to venous congestion and potentially life-threatening airway or neurologic compromise.

• Mechanism: Most commonly caused by extrinsic compression from a mediastinal tumor (e.g., small cell lung cancer, lymphoma) or, less frequently, by endoluminal thrombosis related to indwelling central venous catheters.
• Clinical Presentation: Classic signs include facial, neck, and upper extremity edema (plethora), dyspnea, cough, and a sensation of head fullness. In severe cases, cerebral edema can lead to confusion, headache, and coma.
• Management: Initial supportive care includes elevating the head of the bed, providing supplemental oxygen, and cautious use of diuretics. High-dose corticosteroids (e.g., dexamethasone 10 mg IV bolus followed by 4 mg IV every 6 hours) are given to reduce peritumoral edema and inflammation. Definitive treatment involves endovascular stenting for rapid relief or radiation/chemotherapy guided by tumor histology.

3.2 Spinal Cord Compression

Malignant spinal cord compression occurs when a tumor invades the epidural space or a vertebral body collapses, compressing the thecal sac. This leads to direct cord injury, venous congestion, and ischemia, resulting in progressive neurologic deficits.

• Mechanism: Caused by direct tumor extension from an adjacent vertebra or, less commonly, by vertebral body collapse with retropulsion of bone fragments into the spinal canal.
• Presentation: The hallmark symptom is progressive, often nocturnal, back pain that precedes other neurologic signs. This is followed by motor weakness, sensory loss, and eventually autonomic dysfunction (e.g., bowel/bladder incontinence).
• Management: This is a neurologic emergency. High-dose corticosteroids (dexamethasone 10 mg IV bolus, then 4 mg IV q6h) should be administered immediately to reduce vasogenic edema. Definitive treatment requires urgent consultation with neurosurgery and radiation oncology for consideration of surgical decompression and/or radiation therapy.

3.3 Tumor Lysis Syndrome (TLS)

TLS is a metabolic emergency caused by the massive and rapid breakdown of malignant cells, typically after the initiation of cytotoxic therapy. The breakdown releases large quantities of intracellular contents (potassium, phosphate, and nucleic acids) into the bloodstream, overwhelming the body’s homeostatic mechanisms.

• Biochemical Criteria: Defined by two or more of the following: Uric acid ≥8 mg/dL, Potassium ≥6 mEq/L, Phosphate ≥4.5 mg/dL, or Calcium ≤7 mg/dL.
• Risk Factors: High-risk malignancies include Burkitt lymphoma and acute lymphoblastic leukemia. Other factors are high tumor burden (elevated LDH), and pre-existing renal impairment.
• Management: Prophylaxis is key. This includes aggressive IV hydration (2–3 L/m²/day), and a uric acid-lowering agent. Treatment of established TLS involves continued hydration, aggressive management of electrolyte abnormalities, and often requires rasburicase for rapid reduction of uric acid. Dialysis may be necessary for refractory cases.

3.4 Hypercalcemia of Malignancy

This is one of the most common metabolic emergencies in oncology, driven by several mechanisms including secretion of parathyroid hormone-related peptide (PTHrP), osteolytic metastases, or tumor production of calcitriol.

• Severity: Mild (10.5–12 mg/dL), Moderate (12–14 mg/dL), Severe (>14 mg/dL). Symptoms typically appear in moderate to severe cases.
• Presentation: “Stones, bones, groans, and psychiatric overtones.” Symptoms include lethargy, confusion, polyuria, polydipsia, dehydration, and cardiac arrhythmias.
• Management: The cornerstone is aggressive volume repletion with normal saline (e.g., 200–300 mL/h) to restore intravascular volume and enhance renal calcium excretion. This is followed by agents that inhibit bone resorption, such as bisphosphonates (zoledronic acid, pamidronate) or denosumab. Calcitonin can be used for a rapid but transient effect.

3.5 Neutropenic Fever

Fever in a neutropenic patient is a medical emergency, as the absence of neutrophils removes a critical component of the innate immune system, placing the patient at high risk for overwhelming infection and sepsis.

• Definition: A single oral temperature ≥38.3°C (101°F) or a sustained temperature ≥38.0°C (100.4°F) for one hour, coupled with an absolute neutrophil count (ANC) <500/mm³.
• Management: The highest priority is the administration of empiric, broad-spectrum antibiotics within 60 minutes of presentation. Initial workup includes at least two sets of blood cultures (one peripheral, one from any central line), a chest X-ray, and evaluation for other potential sources of infection.
• Antibiotic Choice: Monotherapy with an anti-pseudomonal beta-lactam (e.g., cefepime, piperacillin-tazobactam, or a carbapenem) is standard. Vancomycin is added for specific indications like suspected line infection, severe mucositis, or hemodynamic instability.

IV. Impact of Comorbidities

Pre-existing chronic conditions significantly modulate the risk, clinical presentation, and pharmacotherapeutic challenges of oncologic emergencies.

4.1 Chronic Kidney Disease (CKD)

CKD impairs the excretion of uric acid, potassium, and phosphate, dramatically increasing the risk and severity of TLS and hypercalcemia. Dose adjustments for many critical medications are required.

4.2 Diabetes Mellitus

Poorly controlled diabetes can impair neutrophil function, increasing infection risk in neutropenic patients. Furthermore, steroid therapy used in many emergencies (e.g., spinal cord compression) can cause severe hyperglycemia, which itself can exacerbate dehydration and electrolyte disturbances.

4.3 Cardiovascular Disease

Patients with heart failure or coronary artery disease are particularly vulnerable. The rapid electrolyte shifts in TLS or hypercalcemia can precipitate life-threatening arrhythmias. Aggressive IV hydration must be carefully balanced against the risk of precipitating acute pulmonary edema.

V. Social Determinants of Health

Socioeconomic factors can create significant barriers to care, leading to delayed diagnosis and treatment of oncologic emergencies.

• Medication Access: The high cost of critical agents like rasburicase and denosumab can be prohibitive. Proactive engagement with social work, case management, and financial counselors is essential.
• Health Literacy: Patients with low health literacy may not recognize or report early warning signs like escalating back pain (spinal cord compression) or fever (neutropenia), leading to presentation at a more advanced, less reversible stage.
• Transportation and Socioeconomic Issues: Difficulty attending outpatient appointments can lead to missed opportunities for monitoring and prophylaxis, resulting in more frequent and severe emergency presentations.

VI. Clinical Implications and Early Recognition Strategies

Proactive, systematic approaches are key to mitigating the impact of oncologic emergencies. Pharmacists and interdisciplinary teams can leverage health information technology and standardized protocols to improve outcomes.

• Standardized Order Sets: For high-risk chemotherapy regimens, order sets should automatically include baseline and serial lab monitoring, triggers for preemptive hydration, and appropriate uric acid-lowering therapy.
• Electronic Health Record (EHR) Alerts: Clinical decision support tools can generate alerts for critical lab values (e.g., new hypercalcemia, rising creatinine in a patient at risk for TLS), prompting immediate clinical review.
• Interdisciplinary Huddles: Daily huddles to review high-risk inpatients allow for real-time adjustments to therapy and ensure a shared mental model among the care team.

By embedding these strategies into routine workflow, healthcare systems can reduce the time to prophylaxis and intervention, directly translating to reduced morbidity and mortality for this vulnerable patient population.